Nonalcoholic Fatty Liver Disease Clinical Trial
Official title:
Effects of Febuxostat for Interventions of Lowering Uric Acid in Patients With Gout With Nonalcoholic Fatty Liver Disease: a Multicenter, Open-label, Randomized, Controlled Study
Verified date | February 2021 |
Source | Ningbo No. 1 Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Nonalcoholic fatty liver disease (NAFLD) is the most common and harmful chronic liver disease. NAFLD accounts for 49.3% of the total number of chronic liver disease patients in China. It is important to effectively prevent and control NAFLD and its related diseases. Previous studies show the level of serum uric acid is significantly elevated in patients with NAFLD. Xanthine oxidase is a key enzyme in uric acid metabolism. It is a new therapeutic target for NAFLD. This study is aimed to further confirm that hyperuricemia is a new risk factor for NAFLD through a large sample prospective study. Furthermore, this study explore whether Xanthine oxidase (XO), a key enzyme in uric acid metabolism, plays an important role in regulating NAFLD.
Status | Not yet recruiting |
Enrollment | 200 |
Est. completion date | March 1, 2022 |
Est. primary completion date | August 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - with informed consent; - Ages 18-65; - Overweight/obesity: BMI =24kg/m2; - A history of gout with serum uric acid levels of > 420µmol/L in men and postmenopausal women, and >360 µmol/L in premenopausal women; - Moderate or above fatty liver was found in the initial screening by ultrasound, and the liver fat content was more than 15% as determined by MRI-PDFF. Exclusion Criteria: - with a history of allergy to febuxostat and allopurinol; - in the acute active phase of gout; - Drinking equivalent to alcohol intake =30g/d(male), =20g/d(female); - Patients with obvious abnormal liver function: serum transaminase (ALT, AST, GGT one of them) or serum bilirubin (direct bilirubin, indirect bilirubin one of them) exceed 2 times the upper limit of normal reference value; Serum albumin <35g/L; - Have a history of viral hepatitis, or serological examination suggests hepatitis virus infection, or have a history of other liver diseases; - Complicated with renal insufficiency (SCr >133µmol/L) or urinary protein +; - Complicated coronary heart disease; - Cardiac dysfunction (cardiac function grade 2 or above); - Complementation with diabetes, or fasting blood glucose >7.8mmol/L, or HbA1c >7.5%; - Severe hypertension, blood pressure = 160/100 mmHg; - Patients with asthma and other respiratory diseases; - Intestinal diseases such as inflammatory bowel disease; - Any history of systemic malignancy in the past 5 years; - Morbid obesity (BMI>37.5kg/m2); - Triglyceride =5.0 mmol/L was found to be significantly abnormal in baseline examination; - had received systemic hormone or immunosuppressive therapy within 3 months prior to screening, or expected to receive hormone or immunosuppressive therapy in the future; - Use of uric-lowering drugs in the 4 weeks before screening: febuxostat, benzobromarone, allopurinol; - Use of other drugs affecting uric acid metabolism were adjusted within 4 weeks before screening: losartan, fenofibrate, irbesartan, thiazide diuretics, loop medullaral diuretics, compound antihypertensive agents containing diuretics; - Other drugs that may affect liver fat content were taken within 4 weeks before screening; - Weight change =5% within 3 months before screening; - Women who are lactating or pregnant or who plan to become pregnant within one year; - were enrolled in other studies within 6 months before screening; - unsuitable for participants to participate in this study. |
Country | Name | City | State |
---|---|---|---|
China | Ningbo first hospital | Ningbo | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Ningbo No. 1 Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Liver fat content of subjects in different groups | Liver fat was assessed based on Magnetic Resonance Imaging (MRI). | at the first week. | |
Primary | Liver fat content of subjects in different groups | Liver fat was assessed based on Magnetic Resonance Imaging (MRI). | at the 24th week . | |
Primary | Liver fat content of subjects in different groups | Liver fat was assessed based on Magnetic Resonance Imaging (MRI). | at the 48th week. | |
Primary | Serum uric acid levels of subjects in different groups | blood samples was assessed after 12 hours overnight fasting for the determination of hematological and biochemical variables, which were measured using an automated hematology analyzer by standard methods. | at the first week | |
Primary | Serum uric acid levels of subjects in different groups | blood samples was assessed after 12 hours overnight fasting for the determination of hematological and biochemical variables, which were measured using an automated hematology analyzer by standard methods. | at the forth week. | |
Primary | Serum uric acid levels of subjects in different groups | blood samples was assessed after 12 hours overnight fasting for the determination of hematological and biochemical variables, which were measured using an automated hematology analyzer by standard methods. | at the twelfth week. | |
Primary | Serum uric acid levels of subjects in different groups | blood samples was assessed after 12 hours overnight fasting for the determination of hematological and biochemical variables, which were measured using an automated hematology analyzer by standard methods. | at the 24th week. | |
Primary | Serum uric acid levels of subjects in different groups | blood samples was assessed after 12 hours overnight fasting for the determination of hematological and biochemical variables, which were measured using an automated hematology analyzer by standard methods. | at the 36th week. | |
Primary | Serum uric acid levels of subjects in different groups | blood samples was assessed after 12 hours overnight fasting for the determination of hematological and biochemical variables, which were measured using an automated hematology analyzer by standard methods. | at the 48th week. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06138327 -
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
|
Phase 1 | |
Completed |
NCT01045499 -
LAGB as a Treatment for Morbid Obesity in Adolescents
|
N/A | |
Completed |
NCT03674476 -
An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function
|
Phase 1 | |
Not yet recruiting |
NCT05495139 -
Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT04988204 -
Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease
|
N/A | |
Recruiting |
NCT04369521 -
Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT01934777 -
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
|
Phase 3 | |
Enrolling by invitation |
NCT00983463 -
Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
|
||
Recruiting |
NCT00658164 -
Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores
|
Phase 3 | |
Recruiting |
NCT02148471 -
Fatty Acids, Genes and Microbiota in Fatty Liver
|
N/A | |
Completed |
NCT06441409 -
Serum Ferritin Levels and Metabolic Dysfunction Associated Steatotic Liver Disease
|
N/A | |
Completed |
NCT03656744 -
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
|
Phase 2 | |
Not yet recruiting |
NCT01735799 -
THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS
|
N/A | |
Completed |
NCT01446276 -
Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT00930384 -
A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis
|
N/A | |
Recruiting |
NCT02469272 -
Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study
|
Phase 1 | |
Completed |
NCT02132780 -
Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease
|
N/A | |
Terminated |
NCT01355575 -
Rifaximin in Fatty Liver Disease
|
Phase 4 | |
Completed |
NCT01399645 -
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes
|
Phase 2 | |
Completed |
NCT01210989 -
Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis
|
N/A |